Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
396.22
+2.68 (0.68%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 389.62 - 398.49
52 week 348.96 - 605.93
Open 398.49
Vol / Avg. 548,059.00/921,307.00
Mkt cap 41.92B
P/E 62.93
Div/yield     -
EPS 6.30
Shares 103.17M
Beta 1.02
Inst. own 71%
Aug 2, 2016
Q2 2016 Regeneron Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 10, 2016
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting - 10:30AM EDT - Add to calendar
Jun 10, 2016
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 10:30AM EDT - Add to calendar
May 26, 2016
Regeneron Pharmaceuticals Inc Science Talent Search New Sponsor Announcement
May 19, 2016
Regeneron Pharmaceuticals Inc at Barclays Biopharmaceuticals CEO/CFO Conference Call Series
May 10, 2016
Regeneron Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2016
Q1 2016 Regeneron Pharmaceuticals Inc Earnings Release
May 5, 2016
Q1 2016 Regeneron Pharmaceuticals Inc Earnings Call
Mar 16, 2016
Regeneron Pharmaceuticals Inc at Barclays Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 13.80% 15.50%
Operating margin 27.42% 30.05%
EBITD margin - 32.33%
Return on average assets 11.55% 13.47%
Return on average equity 17.92% 20.50%
Employees 4,300 -
CDP Score - 59 E

Address

777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 85
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 51
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Executive Vice President - Research and Development
Age: 58
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Daniel P. Van Plew Senior Vice President, General Manager - Industrial Operations and Product Supply
Age: 42
Bio & Compensation  - Reuters
Michael Aberman M.D. Senior Vice President - Strategy and Investor Relation
Age: 44
Bio & Compensation  - Reuters
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 58
Bio & Compensation  - Reuters
Robert J. Terifay Senior Vice President - Commercial
Age: 55
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. Chief Scientific Officer and President - Regeneron Laboratories, Director
Age: 55
Bio & Compensation  - Reuters